Affinage

MEOX1

Homeobox protein MOX-1 · UniProt P50221

Length
254 aa
Mass
28.0 kDa
Annotated
2026-06-10
39 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/7 claims corpus-supported (86%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MEOX1 is a homeodomain transcription factor that controls cell-cycle progression, paraxial mesoderm patterning, and stromal/fibrotic cell-state transitions by directly binding promoters of downstream regulatory genes (PMID:19520072, PMID:34837450). In the developing somite, MEOX1 directly occupies conserved promoter elements of the transcription factors Tbx18 and Uncx to maintain rostro-caudal sclerotome polarity and axial skeleton identity (PMID:19520072), specifies endotomal endothelial precursors that colonize the dorsal aorta to induce haematopoietic stem cells in zebrafish (PMID:25119043), and enforces a G2 cell-cycle arrest in muscle stem cells by directly repressing cyclin B1 (ccnb1) to prevent premature lineage commitment (PMID:28686860). This ccnb1/CCNB1-repression mechanism is redeployed in cancer cells, where direct MEOX1 binding at the CCNB1 transcription start site drives G2 arrest and limits proliferation (PMID:34837450). MEOX1 also imposes G1/S arrest and endothelial senescence through dual modes: DNA-binding-dependent activation of p16INK4a and DNA-binding-independent induction of p21CIP1/WAF1 (PMID:22206000). Across multiple organs MEOX1 acts as a TGF-β1/Smad-inducible effector of fibrotic and hypertrophic remodelling, transcriptionally activating Gata4 in pathological cardiac hypertrophy (PMID:29155983), Cthrc1 to amplify Smad2/3 phosphorylation in cardiac fibrosis (PMID:41362745), and TEAD2, ABHD3, and SPHK1 in hepatic and tumour stromal programs (PMID:42116734, PMID:40100806, PMID:42107070); its own promoter is bound and activated by Smad2/3 downstream of TGF-β1 (PMID:32241049) and by JUN (PMID:39220862). MEOX1 is positioned downstream of Hoxa2 in branchial arch morphogenesis, with Hoxa2 directly activating the Meox1 promoter (PMID:21245383). MEOX1 additionally functions as a FOXP3-dependent, IL-2-inducible regulatory T cell transcription factor required for Treg suppressive capacity (PMID:37559728).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2009 High

    Established that MEOX1 patterns the axial skeleton not by indirect means but through direct transcriptional control of downstream patterning factors, defining its developmental mechanism.

    Evidence Mouse knockout with ChIP for conserved Tbx18/Uncx/Bapx1 promoter elements and proliferation/expression analysis in sclerotome

    PMID:19520072

    Open questions at the time
    • Cofactors mediating activation vs. repression at these promoters not identified
    • Does not address MEOX1 function outside paraxial mesoderm
  2. 2011 High

    Resolved how MEOX1 is wired into developmental hierarchies and revealed two mechanistically distinct activation modes, showing transcriptional output is not uniform across targets.

    Evidence ChIP and promoter mutagenesis placing Meox1 downstream of Hoxa2 in branchial arch; DNA-binding-deficient mutants distinguishing p16INK4a (binding-dependent) from p21CIP1/WAF1 (binding-independent) induction in endothelial cells

    PMID:21245383 PMID:22206000

    Open questions at the time
    • Mechanism of DNA-binding-independent p21 induction not defined
    • Identity of partner factors for binding-independent activation unknown
  3. 2014 High

    Defined a lineage-specifying role for MEOX1 in linking somite-derived endothelium to blood stem cell induction, expanding its function beyond skeletal patterning.

    Evidence Zebrafish loss-of-function genetics, lineage tracing, live imaging, and epistasis with chemokine pathway mutants

    PMID:25119043

    Open questions at the time
    • Direct transcriptional targets driving endotome specification not identified
    • Conservation of the endotome program in mammals unaddressed
  4. 2017 High

    Identified the core cell-cycle mechanism by which MEOX1 governs stem cell dynamics: direct repression of cyclin B1 to enforce G2 arrest and preserve self-renewal.

    Evidence Zebrafish genetics, clonal analysis, ccnb1 promoter binding, and ccnb1-overexpression rescue

    PMID:28686860

    Open questions at the time
    • Whether MEOX1 acts as direct repressor or via recruited corepressors not resolved
    • Signals controlling MEOX1 activity in muscle stem cells unknown
  5. 2018 High

    Extended MEOX1 transcriptional control to pathological cardiac remodelling by identifying Gata4 as a direct effector target.

    Evidence Cardiac-specific gain/loss-of-function mouse models, promoter luciferase, ChIP, and Gata4-knockdown epistasis rescue

    PMID:29155983

    Open questions at the time
    • Upstream signals activating MEOX1 in hypertrophy not defined here
    • Whether Gata4 is the sole hypertrophic target unknown
  6. 2020 Medium

    Positioned MEOX1 as a TGF-β1/Smad-inducible effector and as a growth driver in tumour contexts, establishing both its upstream regulation and oncogenic role.

    Evidence ChIP-qPCR for Smad2/3 on the Meox1 promoter with Smad OE/KD and migration assays in dermal fibroblasts; siRNA knockdown in p53/PTEN-null TNBC with RNA-seq and xenografts

    PMID:32241049 PMID:32467227

    Open questions at the time
    • Direct MEOX1 targets in TNBC (TYK2/STAT5B/STAT6) not shown to be directly bound
    • Single-lab studies
  7. 2021 Medium

    Reinforced the conserved MEOX1→CCNB1 repression axis as a cell-cycle control mechanism operative in cancer cells.

    Evidence ChIP for MEOX1 at the CCNB1 TSS, stable overexpression, and CCNB1-rescue proliferation assays in NSCLC

    PMID:34837450

    Open questions at the time
    • Repression mechanism (corepressor recruitment) not defined
    • Single lab
  8. 2023 Medium

    Revealed an unanticipated immune role for MEOX1 as a FOXP3-dependent regulatory T cell transcription factor required for suppressive function.

    Evidence Transcriptomic and epigenetic analysis across CD4+ conditions, IL-2 stimulation, and siRNA knockdown with suppression assays

    PMID:37559728

    Open questions at the time
    • Direct MEOX1 target genes in Tregs not mapped
    • Relationship to FOXP3 at the molecular level unresolved
  9. 2025 Medium

    Mapped MEOX1 as a central node of multi-organ fibrosis by identifying direct stromal target genes and druggable interfaces.

    Evidence ChIP/luciferase for MEOX1 at ABHD3 and SPHK1 promoters with downstream m6A/S1P axis dissection and in vivo fibrosis/metastasis models; ligand binding to the MEOX1 HOX domain (CETSA/SPR) at the TEAD2 promoter; JUN-MEOX1 promoter disruption by ailanthone

    PMID:39220862 PMID:40100806 PMID:42107070 PMID:42116734

    Open questions at the time
    • Whether these stromal targets are co-regulated by a shared cofactor unknown
    • Direct binding not confirmed for some predicted targets (SERPINE1, RGS4, PAX1)

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unknown what cofactors and chromatin context switch MEOX1 between transcriptional activation and repression at distinct target promoters across development, immunity, and fibrosis.
  • No structural model of MEOX1-DNA-cofactor complexes
  • No unified explanation for activator vs. repressor behavior
  • Mechanism of DNA-binding-independent target activation undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 5
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-1643685 Disease 4 R-HSA-1266738 Developmental Biology 3 R-HSA-1640170 Cell Cycle 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-162582 Signal Transduction 2
Partners
HOXA2JUNSMAD2SMAD3

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2014 In zebrafish, meox1 specifies endotomal endothelial precursor cells within a sub-compartment of the nascent somite (the endotome); these cells migrate to colonize the dorsal aorta and induce haematopoietic stem cell formation via chemokine signalling. Loss of meox1 expands the endotome at the expense of muscle precursors (external cell layer), generating excess endotome-derived cells in the dorsal aorta and a dramatic increase in HSC induction. Zebrafish loss-of-function genetics, lineage tracing, live imaging, epistasis with chemokine pathway mutants Nature High 25119043
2017 Meox1 directly inhibits the cell-cycle checkpoint gene ccnb1 (cyclin B1), thereby initiating G2 cell-cycle arrest within muscle stem cells. Disrupting this G2 arrest causes premature lineage commitment and defects in muscle growth. This establishes a Meox1→ccnb1 repression axis governing muscle stem cell dynamics during zebrafish myotome growth. Zebrafish genetics, clonal analysis, chromatin binding assays (direct inhibition of ccnb1 promoter), rescue experiments with ccnb1 overexpression Cell stem cell High 28686860
2009 Meox1 occupies conserved promoter regions of the transcription factor genes Tbx18 and Uncx (as well as the previously known target Bapx1) in the sclerotome, as shown by chromatin immunoprecipitation. Loss of Meox1 in mice alters relative cell proliferation rates in the rostral vs. caudal sclerotome, disrupts rostro-caudal polarity, and causes atlas-to-basioccipital assimilation—demonstrating a non-redundant role for Meox1 in maintaining sclerotome polarity through direct transcriptional regulation of downstream transcription factors. Mouse homozygous knockout, chromatin immunoprecipitation (ChIP) for conserved promoter elements, proliferation assays, gene expression analysis Developmental biology High 19520072
2011 MEOX1 (and MEOX2) activate p16(INK4a) expression in a DNA-binding-dependent manner, whereas they induce p21(CIP1/WAF1) in a DNA-binding-independent manner, both leading to G1/S cell-cycle arrest and endothelial cell senescence. This demonstrates mechanistically distinct modes of transcriptional activation for two CDK inhibitor target genes. Overexpression of wild-type vs. DNA-binding-deficient MEOX1/MEOX2 mutants in vascular endothelial cells; cell cycle and senescence assays PloS one High 22206000
2011 Meox1 is a direct transcriptional target of Hoxa2 in the second branchial arch: Hoxa2 binds two conserved sites in the Meox1 proximal promoter by ChIP, and these sites are required for Hoxa2-dependent Meox1 promoter activation. Furthermore, Meox1 protein can bind the same DNA sequences recognized by Hoxa2 on Hoxa2 target genes, placing Meox1 genetically downstream of Hoxa2 in branchial arch morphogenesis. ChIP (Hoxa2 on Meox1 promoter), promoter reporter assays with binding-site mutations, Meox1/Meox2 double-mutant mouse genetics, DNA-binding assays Molecular and cellular biology High 21245383
2018 Meox1 transcriptionally activates Gata4 in cardiomyocytes, as demonstrated by promoter-activity assays and ChIP. Meox1 overexpression exacerbates pathological cardiac hypertrophy (familial and pressure-overload models), while knockdown ameliorates it; Gata4 knockdown abolishes these effects, placing Meox1 upstream of Gata4 in pathological hypertrophic remodelling. Cardiac-specific overexpression and knockdown (mouse models), digital gene expression profiling, promoter luciferase assay, ChIP, Gata4 knockdown rescue Cardiovascular research High 29155983
2021 MEOX1 binds to the transcriptional initiation site of CCNB1 (cyclin B1) and suppresses its expression, causing G2-phase cell-cycle arrest and inhibiting NSCLC cell proliferation. CCNB1 overexpression rescues the growth inhibition caused by MEOX1 overexpression, establishing a MEOX1→CCNB1 repression axis in lung cancer cells. ChIP (MEOX1 on CCNB1 promoter), stable MEOX1 overexpression, in vitro/in vivo proliferation assays, CCNB1 rescue overexpression Environmental toxicology Medium 34837450
2020 Combined p53- and PTEN-deficiency activates MEOX1 expression in TNBC cells. MEOX1 knockdown in these cells decreases expression of TYK2, STAT5B, and STAT6, abolishes cell proliferation in vitro, and inhibits tumor growth in vivo, indicating MEOX1 is required for growth downstream of combined p53/PTEN loss and upstream of JAK-STAT signalling components. siRNA double knockdown of p53 and PTEN, MEOX1 siRNA knockdown, RNA-Seq, immunoblotting, in vivo xenograft The Journal of biological chemistry Medium 32467227
2020 TGF-β1 transcriptionally upregulates Meox1 in adult human dermal fibroblasts via Smad2 and Smad3, which directly bind the Meox1 promoter as shown by ChIP-qPCR. Meox1 overexpression promotes, and Meox1 knockdown reduces, fibroblast migration in scratch and Transwell assays. Transcriptome sequencing, RT-PCR, ChIP-qPCR (Smad2/3 on Meox1 promoter), Smad overexpression and siRNA knockdown, scratch/Transwell migration assays Zhonghua shao shang za zhi Medium 32241049
2024 Ailanthone (AIL) suppresses MEOX1 expression by disrupting the interaction between the transcription factor JUN and the MEOX1 promoter, thereby blocking JUN-dependent MEOX1 activation. MEOX1 knockdown inhibits TGF-β1-induced fibroblast activation and endothelial-to-mesenchymal transition in vitro and ameliorates bleomycin-induced pulmonary fibrosis in vivo. High-throughput small-molecule screening, promoter-binding disruption assay, MEOX1 knockdown in fibroblasts and endothelial cells, bleomycin mouse model, in vitro fibroblast activation assays Acta pharmaceutica Sinica. B Medium 39220862
2024 MEOX1 promotes myofibroblast apoptosis resistance in pulmonary fibrosis by transcriptionally upregulating RGS4 (G-protein signaling regulatory factor 4) in TGF-β1-induced myofibroblasts. MEOX1 silencing enhances myofibroblast apoptosis and attenuates fibrosis progression in bleomycin-treated mice. Bioinformatics target prediction, siRNA-mediated MEOX1 knockdown, in vitro TGF-β1-induced myofibroblast model, apoptosis assays, bleomycin mouse model Journal of cellular physiology Low 39319990
2026 Meox1 transcriptionally activates Cthrc1 (collagen triple helix repeat containing 1) in cardiac fibroblasts, which promotes Smad2/3 phosphorylation and cardiac fibroblast-to-myofibroblast conversion. Meox1 knockdown attenuates cardiac fibrosis post-MI; Cthrc1 overexpression abolishes this cardioprotection, establishing a Meox1→Cthrc1→p-Smad2/3 signalling axis. Mouse MI model with Meox1 knockdown, primary cardiac fibroblast gain/loss-of-function, ChIP or promoter analysis for Cthrc1, Smad2/3 phosphorylation assays, Cthrc1 rescue overexpression in vivo and in vitro International journal of biological sciences Medium 41362745
2025 MEOX1 directly binds the ABHD3 gene promoter to activate its transcription, thereby driving circABHD3 generation. circABHD3 promotes YTHDF2-dependent m6A-mediated degradation of YPEL3 mRNA, activating β-catenin signalling and exacerbating hepatic fibrosis through EMT and mitochondrial impairment. Luciferase reporter assay, ChIP (MEOX1 on ABHD3 promoter), methylated RNA immunoprecipitation (MeRIP), RIP and RNA pull-down for circABHD3-YTHDF2 interaction, in vivo CCl4/BDL fibrosis mouse models with knockdown PLoS genetics Medium 40100806
2026 MEOX1 binds the TEAD2 promoter (at the -988 to -982 nt region) to activate TEAD2 transcription in hepatic stellate cells, stimulating Hippo signalling target transcription and promoting HSC activation and proliferation. Ligustilide binds the HOX domain of MEOX1 (confirmed by CETSA and SPR), inhibiting its function and alleviating hepatic fibrosis. ChIP, promoter deletion/mutation assays, CETSA, SPR, siRNA knockdown, in vivo CCl4 mouse model, LX-2 cell functional assays British journal of pharmacology Medium 42116734
2023 MEOX1 is expressed specifically in CD4+ Treg cells at levels comparable to FOXP3, is upregulated by IL-2, and has a permissive epigenetic landscape exclusively in Tregs. MEOX1 knockdown profoundly alters downstream gene expression programs and impairs Treg suppressive capacity, identifying MEOX1 as a FOXP3-dependent Treg transcription factor. Transcriptomic dataset analysis (48 CD4+ T cell conditions), reverse network engineering, epigenetic analysis, IL-2 stimulation, siRNA knockdown with functional suppression assays Frontiers in immunology Medium 37559728
2021 Meox1 regulates SDF-1α expression in vascular smooth muscle cells (VSMCs) via activation of CDC42, and promotes CXCR4 expression in Sca-1+ progenitor cells also through CDC42. Meox1 knockdown abolishes Sca-1+ progenitor cell accumulation and migration into the neointima after vascular injury, and CXCR4 inhibition similarly blocks these effects. Rat carotid balloon injury model, adenoviral shRNA-mediated Meox1 knockdown, CDC42 inhibitor (ZCL278), CXCR4 inhibitor (AMD3100), immunostaining for PCNA/Meox1, neointima quantification Stem cell research & therapy Low 34233723
2025 TGF-β1 upregulates MEOX1 expression in lung fibroblasts through the NOX4-ROS-Smad pathway. Fibroblast-specific MEOX1 knockdown protects mice from bleomycin-induced pulmonary fibrosis and reduces CTGF expression. In vitro, MEOX1 knockdown abolishes TGF-β1-induced mitophagy deficiency by downregulating CTGF, thereby inhibiting fibroblast senescence and over-activation. RNA-seq, bleomycin mouse model with AAV-shMEOX1 (fibroblast-specific), NOX4/ROS pathway inhibition, in vitro lung fibroblast assays European journal of pharmacology Low 40780596
2026 In glioblastoma cells, MEOX1 represses PAX1, thereby promoting tumor cell proliferation, migration, and invasion. PAX1 overexpression in GBM cells inhibits Treg differentiation from co-cultured CD4+ T cells, while PAX1 knockdown promotes it, linking the MEOX1→PAX1 repression axis to both intrinsic tumor aggressiveness and immunosuppression in the tumor microenvironment. GBM cell line gain/loss-of-function, functional proliferation/migration/invasion assays, co-culture CD4+ T cell Treg differentiation assays, PAX1 overexpression rescue Scientific reports Low 41692908
2026 MEOX1 binds the SPHK1 (sphingosine kinase 1) promoter to activate S1P synthesis in ovarian cancer cells, driving a dual autocrine (S1PR3-dependent proliferation/migration) and paracrine (S1P/S1PR1-dependent reprogramming of fibroblasts to VEGF-C-secreting CAFs) program that promotes lymphangiogenesis and lymph node metastasis. SPHK1 inhibition blunts these phenotypes; S1P supplementation restores them. MEOX1 overexpression in vivo LNM model, spatial transcriptomics, immunostaining, promoter binding assay (MEOX1 on SPHK1 promoter), SPHK1 inhibitor and S1P rescue experiments, CAF-LEC co-culture, 113-patient cohort validation Advanced science Medium 42107070
2025 MEOX1 promotes SERPINE1 transcription in hepatic stellate cells (HSCs), thereby activating HSCs and promoting MASH-related liver fibrosis. MEOX1 knockdown suppresses HSC activation, proliferation, and migration; SERPINE1 was identified as the critical downstream target by RNA-seq. RNA-seq in MEOX1-knockdown HSCs, in vitro HSC functional assays (activation, proliferation, migration), MASH mouse model, AlphaFold/PyMOL interaction prediction The International journal of biological markers Low 40270091
2020 PPARα directly regulates MEOX1 expression in cardiomyocytes; PPARα gene delivery reduces cardiac dysfunction and mitochondria-dependent apoptosis in doxorubicin-treated mice, and these cardioprotective effects are abolished by MEOX1 knockdown, placing MEOX1 downstream of PPARα in this cardioprotective pathway. rAAV9-mediated PPARα delivery in mice, MEOX1 knockdown rescue, cardiac function (echocardiography), apoptosis assays Frontiers in pharmacology Low 33132907

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. American journal of medical genetics 241 12116252
2014 Haematopoietic stem cell induction by somite-derived endothelial cells controlled by meox1. Nature 127 25119043
2017 Muscle Stem Cells Undergo Extensive Clonal Drift during Tissue Growth via Meox1-Mediated Induction of G2 Cell-Cycle Arrest. Cell stem cell 67 28686860
2013 Mutations in MEOX1, encoding mesenchyme homeobox 1, cause Klippel-Feil anomaly. American journal of human genetics 63 23290072
2011 Mechanisms of MEOX1 and MEOX2 regulation of the cyclin dependent kinase inhibitors p21 and p16 in vascular endothelial cells. PloS one 60 22206000
2013 Mutation in MEOX1 gene causes a recessive Klippel-Feil syndrome subtype. BMC genetics 48 24073994
2009 Lack of the mesodermal homeodomain protein MEOX1 disrupts sclerotome polarity and leads to a remodeling of the cranio-cervical joints of the axial skeleton. Developmental biology 47 19520072
2007 A comparative analysis of Meox1 and Meox2 in the developing somites and limbs of the chick embryo. The International journal of developmental biology 35 17939123
2018 Meox1 accelerates myocardial hypertrophic decompensation through Gata4. Cardiovascular research 30 29155983
2021 MEOX1 suppresses the progression of lung cancer cells by inhibiting the cell-cycle checkpoint gene CCNB1. Environmental toxicology 28 34837450
2020 Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer. The Journal of biological chemistry 26 32467227
2018 Skeletal malformations of Meox1-deficient zebrafish resemble human Klippel-Feil syndrome. Journal of anatomy 23 30277257
2011 Transient activation of meox1 is an early component of the gene regulatory network downstream of hoxa2. Molecular and cellular biology 22 21245383
2020 PPARα Ameliorates Doxorubicin-Induced Cardiotoxicity by Reducing Mitochondria-Dependent Apoptosis via Regulating MEOX1. Frontiers in pharmacology 21 33132907
2024 Ailanthone ameliorates pulmonary fibrosis by suppressing JUN-dependent MEOX1 activation. Acta pharmaceutica Sinica. B 20 39220862
2007 Diaphanospondylodysostosis: six new cases and exclusion of the candidate genes, PAX1 and MEOX1. American journal of medical genetics. Part A 16 17764081
2022 The role of MEOX1 in non-neoplastic and neoplastic diseases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 13 36495659
2021 Spatio-temporal model of Meox1 expression control involvement of Sca-1-positive stem cells in neointima formation through the synergistic effect of Rho/CDC42 and SDF-1α/CXCR4. Stem cell research & therapy 7 34233723
2024 MEOX1 triggers myofibroblast apoptosis resistance, contributing to pulmonary fibrosis in mice. Journal of cellular physiology 6 39319990
2021 Expression quantitative trait loci for ETV4 and MEOX1 are associated with adult asthma in Japanese populations. Scientific reports 6 34552174
2024 Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1. Journal of ovarian research 5 38486335
2023 Identification of the novel FOXP3-dependent Treg cell transcription factor MEOX1 by high-dimensional analysis of human CD4+ T cells. Frontiers in immunology 4 37559728
2018 Silencing of MEOX1 Gene Inhibits Proliferation and Promotes Apoptosis of LNCaP Cells in Prostate Cancer. Cancer biotherapy & radiopharmaceuticals 4 30543460
2017 Data on the involvement of Meox1 in balloon-injury-induced neointima formation of rats. Data in brief 4 29204471
2020 [Mechanism of transcriptional regulation of Meox1 by transforming growth factor β (1) and its effect on cell migration of adult human dermal fibroblasts]. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns 3 32241049
2026 Meox1 Promotes Cardiac Fibrosis and Pathological Remodeling following Myocardial Infarction through Cthrc1/p-Smad2/3 Signaling. International journal of biological sciences 1 41362745
2026 DNA methylation-mediated silencing of MEOX1 promotes glycolysis and immune evasion in colorectal cancer cells through inhibition of GLP2R transcription. Cell & bioscience 1 41612494
2025 MEOX1-mediated transcriptional regulation of circABHD3 exacerbates hepatic fibrosis through promoting m6A/YTHDF2-dependent YPEL3 mRNA decay to activate β-catenin signaling. PLoS genetics 1 40100806
2025 Organelle stresses and energetic metabolisms promote endothelial-to-mesenchymal transition and fibrosis via upregulating FOSB and MEOX1 in Alzheimer's disease. Frontiers in molecular neuroscience 1 40919531
2024 Regulatory Role of Meox1 in Muscle Growth of Sebastes schlegelii. International journal of molecular sciences 1 38732090
2022 The squiggle tail (squig) mutation in mice is associated with a deletion in the mesenchyme homeobox 1 (Meox1) gene. BMC research notes 1 36138442
2026 The MEOX1-PAX1 axis coordinately regulates tumor cell malignancy and Treg differentiation in glioblastoma. Scientific reports 0 41692908
2026 Meox1 promotes hepatocellular carcinoma progression potentially via regulation of cell cycle and p21 expression. Cell adhesion & migration 0 42002886
2026 MEOX1 Coordinates Autocrine-Paracrine Programs via SPHK1/S1P to Promote Lymph Node Metastasis in Ovarian Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 0 42107070
2026 Ligustilide alleviates hepatic fibrosis by targeting the mesenchymal homeobox 1 (MEOX1)- transcriptional enhanced associate domain factor 2 (TEAD2) signalling axis. British journal of pharmacology 0 42116734
2026 MEOX1 Inhibits Growth and Metastasis of Salivary Adenoid Cystic Carcinoma. Current issues in molecular biology 0 42193090
2025 Identification of MEOX1 as a potential target in metabolic dysfunction-associated steatohepatitis-related liver fibrosis. The International journal of biological markers 0 40270091
2025 Transcription factor MEOX1 accelerates pulmonary fibrosis by regulating mitophagy and senescence. European journal of pharmacology 0 40780596
2025 Role of Meox1 in promoting lung tumor vascularization and impairing CD8+ T cell mediated immunity. Frontiers in oncology 0 40919158

Missed literature

Know a paper Affinage missed for MEOX1? Flag it for the maintainers and the community.

No submissions yet.